



**DECEMBER 31,
2024**

HALF YEARLY REPORT

**WORKING TODAY
FOR A HEALTHIER TOMORROW**

Macter International Limited

CONTENTS

Company Information	02
Directors' Review Report	04
Auditors' Review Report	10
Un-consolidated Condensed Interim Statement of Financial Position	11
Un-consolidated Condensed Interim Statement of Profit or Loss	12
Un-consolidated Condensed Interim Statement of Comprehensive Income	13
Un-consolidated Condensed Interim Statement of Changes in Equity	14
Un-consolidated Condensed Interim Statement of Cash Flows	15
Notes to the Un-consolidated Condensed Interim Financial Statements	16
Consolidated Condensed Interim Statement of Financial Position	26
Consolidated Condensed Interim Statement of Profit or Loss	27
Consolidated Condensed Interim Statement of Comprehensive Income	28
Consolidated Condensed Interim Statement of Changes in Equity	29
Consolidated Condensed Interim Statement of Cash Flows	30
Notes to the Consolidated Condensed Interim Financial Statements	31

COMPANY INFORMATION

BOARD OF DIRECTORS

1.	Mr. Amanullah Kassim	Chairman	Independent Director
2.	Mr. Asif Misbah	Chief Executive	Executive Director
3.	Mr. Swaleh Misbah Khan		Executive Director
4.	Sheikh Muhammed Waseem		Non-Executive Director
5.	Sheikh Perwez Ahmed		Non-Executive Director
6.	Mr. Jawwad Ahmed Farid		Independent Director
7.	Ms. Masarrat Misbah		Non-Executive Director
8.	Mr. Muhammad Ather Sultan		Non-Executive Director
9.	Shaikh Abdus Sami		Independent Director

BOARD AUDIT COMMITTEE

1.	Shaikh Abdus Sami	Chairman
2.	Sheikh Muhammed Waseem	Member
3.	Mr. Muhammad Ather Sultan	Member

BOARD HUMAN RESOURCE AND REMUNERATION COMMITTEE

1.	Mr. Jawwad Ahmed Farid	Chairman
2.	Mr. Asif Misbah	Member
3.	Mr. Muhammad Ather Sultan	Member

CHIEF FINANCIAL OFFICER

Syed Naveed Rizvi

COMPANY SECRETARY

Mr. Asif Javed

INTERNAL AUDITORS

KPMG Taseer Hadi & Co.
Chartered Accountants

EXTERNAL AUDITORS

A.F. Ferguson & Co
Chartered Accountants

SHARIAH ADVISOR

Mufti Muhammad Najeeb Khan

BANKERS

Al Baraka (Pakistan) Limited
Allied Bank Ltd - Islamic Banking
Askari Bank Limited- Islamic Banking Branch
Bank Alfalah Limited- Islamic Banking
Bank Al Habib Limited - Islamic Banking Branch
Bankislami Pakistan Limited
Dubai Islamic Bank Pakistan Limited
Habib Bank Limited -Islamic Banking Branch
Habib Metropolitan Bank Pakistan Limited - Islamic Banking Branch
MCB Bank Limited
MCB Islamic Bank Limited
Meezan Bank Limited
The Bank of Punjab- Taqwa Islamic Banking

SHARE REGISTRAR

F.D. Registrar Services (Pvt) Limited
17th Floor, Saima Trade Tower-A
I. I. Chundrigar Road, Karachi
Telephone: + 92 21 32271905-6
Fax: + 92 21 32621233
Email: fdregistrar@yahoo.com

REGISTERED OFFICE

F-216, SITE, Karachi - 75700
Telephone: +92 21 32591000
Fax: +92 21 32564236
Email: info@macter.com

WEBSITE

www.macter.com

DIRECTORS' REVIEW REPORT

We are pleased to present the un-audited un-consolidated and consolidated condensed interim financial statements for the half year ended December 31, 2024:

FINANCIAL RESULTS

Rupees Millions

DESCRIPTION	July - December			
	Unconsolidated		Consolidated	
	2024	2023	2024	2023
Turnover - Net	4,920	3,581	5,144	3,808
Gross profit	2,202	1,454	2,341	1,585
Gross margin	45%	41%	45%	42%
Operating Profit	625	258	650	278
Operating Margin	13%	7%	13%	7%
Profit before tax	577	205	585	214
Profit after tax	392	195	396	200

FINANCIAL PERFORMANCE

Net turnover for the period ending 31st December 2024 was Rupees 4,920 million with a growth of 37% over same period last year. All revenue categories (prescription, institution and export) registered high double digit growth. Exports grew by 50% which reflects the company's intent to significantly increase export share of total revenues. Profit volumes and profitability have shown significant improvement during the period under review. This is the result of consistent efforts over the past years to bring Macter's financial performance at par with the best performing pharmaceutical companies in Pakistan. There were very strong headwinds - high currency devaluation and inflation, high interest rates, economic instability, regulatory hurdles (such as removal of sales tax input adjustment and delays in new product registrations), price controls and increasing competition. As some key external factors have stabilized or improved and pricing of non-essential medicines have been deregulated the full impact of the turnaround strategy is now becoming evident.

One of the leading indicators of sustainable growth for a pharmaceutical company is its new product pipeline. Macter is committed to introducing high quality and innovative medicines to improve patient health outcomes in Pakistan and across the world. We are pleased to inform that we launched a number of innovative new products during the current period such as:

- Upacnet (Upadacitinib) indicated for inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, Crohn's disease, and axial spondyloarthritis
- Indyco M (Glycopyrronium + Indacaterol + Mometasone), a triple Dry Powder Inhaler for the treatment of asthma
- Digebro Syrup for irritable bowel syndrome, abdominal discomfort, cramps, heartburn, diarrhea, and chronic constipation
- SEGLUTIDE (Semaglutide), Pakistan's first rDNA-based Semaglutide for diabetes and obesity

We continue to focus on Research and Development, Manufacturing Excellence and Commercial Excellence to ensure that we are the first company to launch innovative products in Pakistan and globally and make them commercially successful for company's sustainable growth.

EARNINGS PER SHARE

Earnings per share as per unconsolidated financial statements for the period July-December 2024 was Rs. 8.56 versus earnings per share of Rs. 4.26 during same period last year.

FUTURE OUTLOOK

The Pakistani retail pharmaceutical market surpassed the 1tr PKR mark (USD 3.69bn) with a value growth of 21.45% and unit growth of 2.85% (December 2024 IQVIA). Macter was reported in the same period with 12bn sales and 35% growth and ranking of 17th amongst national companies. Despite intense and increasing competition, Pakistan pharmaceutical market has significant growth potential driven by increasing demand for quality healthcare products. The export potential for quality and innovation focused Pakistani companies is many times more. The playbook for demonstrating sustainable high growth in Pakistan and globally is the same. And so we continue to invest on our people, innovation and quality and are confident that Macter will emerge as one of the leading companies in Pakistan and in all international markets that we serve.

As a responsible corporate citizen we will continue to play our role in community engagement and positively impact our society and the environment.

ACKNOWLEDGEMENTS

The Board of Directors appreciate the commitment, dedication, and devotion of all our employees who have worked to ensure supply of our lifesaving medicines and deliver strong performance. We acknowledge the support and cooperation received from our valued shareholders, customers, distributors, suppliers, financial institutions and regulatory authorities.

We would like to especially acknowledge the Government for deregulating pricing of non-essential drugs. This has given a lifeline to the industry to pass-through some inflation and the necessary confidence to investors and shareholders about the viability of the industry. This will lead to long term investments in technical capabilities which will enhance quality and global competitiveness of the industry. We remain committed to availing this option in a responsible manner and in the best interests of patients and society.

All praise and gratitude to Allah SWT for His continued blessings.

On behalf of the board



Asif Misbah
Chief Executive

Karachi
February 22, 2025



Muhammad Ather Sultan
Director

فی حصص منافع

جولائی تا دسمبر 2024ء کے دوران غیر مدغم شدہ مالیاتی گوشواروں کے مطابق فی حصص آمدنی 8.56 روپے رہی جو گزشتہ سال کے اسی عرصے کے دوران 4.26 روپے تھی۔

مستقبل کا جائزہ

پاکستانی ریٹیل فارماسیوٹیکل مارکیٹ نے 21.45 فیصد کی قدر میں اضافے اور یونٹ میں 2.85 فیصد (دسمبر 2024-IQVIA) کے ساتھ ایک کھرب پاکستانی روپے (3.69 ارب امریکی ڈالر) کی حد عبور کی۔ اسی عرصے میں میکٹر کو 12 ارب کی فروخت اور 35 فیصد اضافے کے ساتھ قومی کمپنیوں میں 17 ویں نمبر پر رپورٹ کیا گیا۔ شدید اور بڑھتی ہوئے مسابقت کے باوجود، پاکستان کی فارماسیوٹیکل مارکیٹ میں اعلیٰ معیار کی صحت کی دیکھ بھال کی مصنوعات کی بڑھتی ہوئی طلب کی وجہ سے نمایاں ترقی کی صلاحیت موجود ہے۔ اعلیٰ معیار اور جدت پر توجہ مرکوز کرنے والی پاکستانی کمپنیوں کے لئے برآمدات کی صلاحیت کئی گنا زیادہ ہے۔ پاکستان اور عالمی سطح پر پائیدار اعلیٰ نمو کو ظاہر کرنے کے لئے کھیل کی کتاب ہے۔ لہذا ہم اپنے لوگوں، جدت اور معیار پر سرمایہ کاری جاری رکھے ہوئے ہیں اور ہمیں یقین ہے کہ میکٹر پاکستان اور ان تمام بین الاقوامی مارکیٹوں میں ایک معروف کمپنی کے طور پر ابھرے گا جہاں ہم خدمات فراہم کرتے ہیں۔

ایک ذمہ دار کارپوریٹ شہری کی حیثیت سے ہم معاشرتی روابط میں اپنا کردار ادا کرتے رہیں گے اور معاشرے اور ماحول پر مثبت اثرات مرتب کریں گے۔

اعتراف


بورڈ آف ڈائریکٹرز اپنے تمام ملازمین کے عزم، لگن اور قربانی کو سراہتے ہیں جنہوں نے ہماری زندگی بچانے والی ادویات کی فراہمی کو یقینی بنانے اور مضبوط کارکردگی کی فراہمی کو یقینی بنانے کے لئے کام کیا ہے۔ ہم اپنے قابل قدر شیئرز ہولڈرز، کسٹمرز، ڈسٹری بیوٹرز، سپلائرز، مالیاتی اداروں اور ریگولیٹری اتھارٹیز کی حمایت اور تعاون کا اعتراف کرتے ہیں۔

ہم خاص طور پر حکومت کا شکریہ ادا کرنا چاہتے ہیں کہ انہوں نے غیر ضروری ادویات کی قیمتوں کو ڈی ریگولیت کر دیا ہے۔ اس سے صنعت کو افراط زر کا کچھ بوجھ برداشت کرنے کا موقع ملا ہے اور سرمایہ کاروں اور شیئرز ہولڈرز کو صنعت کی پائیداری کے بارے میں ضروری اعتماد حاصل ہوا ہے۔ اس سے تکنیکی صلاحیتوں میں طویل مدتی سرمایہ کاری کی راہ ہموار ہوگی جو صنعت کے معیار اور عالمی مسابقت کو بڑھادے گی۔ ہم اس آپشن کو ذمہ داری کے ساتھ اور مریضوں اور معاشرت کے بہترین مفاد میں استعمال کرنے کے لیے پُر عزم ہیں۔

مسلسل فضل و کرم پر تمام تعریفیات اور تشکرات اللہ سبحانہ و تعالیٰ کے لیے ہے۔

مخائب بورڈ


محمد اسلم سلطان
ڈائریکٹر


آصف مصباح
چیف ایگزیکٹو

کراچی

فروری 22، 2025ء

ڈائریکٹرز جائزہ رپورٹ

ہم 31 دسمبر، 2024ء کو ختم ہونے والی ششماہی کے غیر آڈٹ شدہ غیر مدغم شدہ اور مدغم شدہ مختصر عبوری مالیاتی گوشوارے پیش کرتے ہوئے خوشی محسوس کر رہے ہیں۔

مالیاتی نتائج

(روپے ملین میں)

مندرجات	جولائی - دسمبر			
	مدغم شدہ		غیر مدغم شدہ	
	2023	2024	2023	2024
فروخت خالص	3,808	5,144	3,581	4,920
مجموعی منافع	1,585	2,341	1,454	2,202
آپریٹنگ منافع	278	650	258	625
قبل از ٹیکس منافع	214	585	205	577
بعد از ٹیکس منافع	200	396	195	392

مالیاتی کارکردگی

31 دسمبر 2024ء کو ختم ہونے والی مدت کے دوران خالص کاروبار 4,920 ملین روپے تھا جو گزشتہ سال کے اسی عرصے کے مقابلے میں 37 فیصد کی ترقی کو ظاہر کرتا ہے۔ تمام محصولاتی زمروں (نئے کی دوائیں، ادارہ جاتی اور برآمدات) نے دوہرے ہندسوں میں ترقی ریکارڈ کی۔ برآمدات میں 50 فیصد اضافہ ہوا جو کمپنی کے مجموعی محصولات کے برآمدات کے حصے کو کل آمدنی میں نمایاں اضافہ کرنے کے عزم کی عکاسی کرتا ہے۔ زیر جائزہ مدت کے دوران منافع کے حجم اور منافیت میں نمایاں بہتری آئی ہے۔ یہ میکٹر کی مالیاتی کارکردگی کو پاکستان میں بہترین کارکردگی کا مظاہرہ کرنے والی دواساز کمپنیوں کے برابر لانے کے لئے گزشتہ سالوں میں مسلسل کوششوں کا نتیجہ ہے۔ کرنسی کی قدر میں کمی اور افراط زر، بلند شرح سود، معاشی عدم استحکام، ریگولیٹری رکاوٹیں (جیسے سیلز ٹیکس ان پٹ ایڈجسٹمنٹ کا خاتمہ اور نئی مصنوعات کی رجسٹریشن میں تاخیر)، قیمتوں پر کنٹرول اور بڑھتی ہوئی مسابقت۔ چونکہ کچھ اہم بیرونی عوامل مستحکم یا بہتر ہوئے ہیں اور غیر ضروری ادویات کی قیمتوں کو ڈی ریگولیت کیا گیا ہے لہذا تہذیبی کی حکمت عملی کا مکمل اثراب واضح ہو رہا ہے۔

ایک دواساز کمپنی کے لئے پائیدار ترقی کے اہم اشارے میں سے ایک اس کی نئی مصنوعات کی پائپ لائن ہے۔ میکٹر پاکستان اور دنیا بھر میں مرلیٹوں کی صحت کے نتائج کو بہتر بنانے کے لئے اعلیٰ معیار اور جدید ادویات متعارف کرانے کے لئے پر عزم ہے۔ ہمیں یہ بتاتے ہوئے خوشی ہو رہی ہے کہ ہم نے موجودہ مدت کے دوران متعدد جدید نئی مصنوعات متعارف کروائی ہیں جیسے:

- Upacnet (Upadacitinib) جو سوزش کی حالتوں جیسے روماتائیز آرٹھرائٹس، سوریک آرٹھرائٹس، ایٹاپک ڈرمنیٹیس، کروں کی بیماری، اور ایکسل سپونڈیلو آرٹھرائٹس کی نشاندہی کی گئی ہے۔
- Indycy M (گلیوسیرونیٹیم + اینڈیکٹرول + موبیتاسون) دمہ کے علاج کے لئے ایک ٹریپ ڈرائی پاؤڈر اینٹی
- Digebro Syrup (دیجیبرو سیرپ) ریٹینیل پاؤلنڈروم پیٹ کی تکلیف، درد، سینے میں جلن، اسہال، اور دائمی قبض کے لئے
- SEMAGLUTIDE (Semaglutide) ڈیپٹیٹس اور موناپے کے لیے پاکستان کا پہلا آر ڈی این اے جیٹ سیموگلوٹائڈ

ہم ریسرچ اینڈ ڈیولپمنٹ، مینوفیکچرنگ ایکٹیویٹیز اور کمرشل ایکٹیویٹیز پر توجہ مرکوز رکھے ہوئے ہیں تاکہ اس بات کو یقینی بنایا جاسکے کہ ہم پاکستان اور عالمی سطح پر جدید مصنوعات متعارف کرنے والی پہلی کمپنی بنیں اور ان کو کمپنی کی پائیدار ترقی کے لئے تجارتی طور پر کامیاب بنائیں۔

This page left blank intentionally.

**UNCONSOLIDATED CONDENSED INTERIM
FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED
DECEMBER 31, 2024**



A.F. FERGUSON & CO.

INDEPENDENT AUDITOR'S REVIEW REPORT**To the members of Macter International Limited****Report on review of Interim Financial Statements****Introduction**

We have reviewed the accompanying unconsolidated condensed interim statement of financial position of Macter International Limited as at December 31, 2024 and the related unconsolidated condensed interim statement of profit or loss, unconsolidated condensed interim statement of comprehensive income, unconsolidated condensed interim statement of changes in equity, unconsolidated condensed interim statement of cash flows, and notes to and forming part of the unconsolidated condensed interim financial statements for the half year then ended (here-in-after referred to as the "interim financial statements"). Management is responsible for the preparation and presentation of these interim financial statements in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on these interim financial statements based on our review. The figures of the unconsolidated condensed interim statement of profit or loss and unconsolidated condensed interim statement of comprehensive income for the quarters ended December 31, 2024 and December 31, 2023 have not been reviewed, as we are required to review only the cumulative figures for the half year ended December 31, 2024.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements are not prepared, in all material respects, in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting.

The engagement partner on the audit resulting in this independent auditor's report is Azhar Hussain.

A. F. Ferguson & Co.
Chartered Accountants
Karachi

Date: February 28, 2025

UDIN: RR202410290M8b7lls5J

*A. F. FERGUSON & CO., Chartered Accountants, a member firm of the PwC network
State Life Building No. 1-C, I.I. Chundrigar Road, P.O. Box 4716, Karachi-74000, Pakistan
Tel: +92 (21) 32426682-6/32426711-5; Fax: +92 (21) 32415007/32427938/32424740; <www.pwc.com/pk>*

■ KARACHI ■ LAHORE ■ ISLAMABAD

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION (UN-AUDITED)
AS AT DECEMBER 31, 2024

		December 31, 2024	June 30, 2024
	Note (Rupees in '000)	
		Un-audited	Audited
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	6	2,313,776	2,067,234
Intangible assets		1,771	2,064
Long-term investment	7	300,000	300,000
Long-term loans		3,691	1,829
Long-term deposits		90,383	73,183
Deferred taxation - net		11,168	14,052
		<u>2,720,789</u>	<u>2,458,362</u>
CURRENT ASSETS			
Stores and spares		22,842	18,114
Stock-in-trade	8	2,741,223	1,971,962
Trade debts	9	576,439	389,899
Loans and advances		207,836	229,886
Trade deposits, prepayments and other receivables		116,632	91,205
Sales tax refundable		-	9,626
Taxation - net		-	59,806
Short-term investments	10	16,838	-
Cash and bank balances	11	61,314	184,251
		<u>3,743,124</u>	<u>2,954,749</u>
TOTAL ASSETS		<u>6,463,913</u>	<u>5,413,111</u>
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Issued, subscribed and paid-up capital		458,111	458,111
Capital reserve		1,225,860	1,225,860
Revenue reserve - accumulated profit		1,859,333	1,513,138
		<u>3,543,304</u>	<u>3,197,109</u>
NON-CURRENT LIABILITIES			
Deferred liabilities		277,255	256,080
Long-term financing	12	411,213	321,887
Lease liabilities		57,893	85,862
		<u>746,361</u>	<u>663,829</u>
CURRENT LIABILITIES			
Trade and other payables	13	1,885,555	1,339,338
Current portion of long-term financing	12	129,982	99,247
Current portion of lease liabilities		33,815	27,554
Current portion of long term provision		85,650	85,484
Sales tax payable		13,214	-
Taxation - net		25,449	-
Unclaimed dividends		583	550
		<u>2,174,248</u>	<u>1,552,173</u>
TOTAL LIABILITIES		<u>2,920,609</u>	<u>2,216,002</u>
CONTINGENCIES AND COMMITMENTS	14		
TOTAL EQUITY AND LIABILITIES		<u>6,463,913</u>	<u>5,413,111</u>

The annexed notes 1 to 20 form an integral part of these unconsolidated condensed interim financial statements.


CHIEF FINANCIAL OFFICER


CHIEF EXECUTIVE


DIRECTOR

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Note	Quarter Ended		Half Year Ended	
		December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
(Rupees in '000)					
Revenue from contracts with customers	15	2,754,993	1,923,252	4,919,529	3,580,613
Cost of sales		(1,458,132)	(1,101,727)	(2,717,704)	(2,126,834)
Gross profit		1,296,861	821,525	2,201,825	1,453,779
Selling and distribution expenses		(658,599)	(523,796)	(1,232,007)	(987,012)
Administrative expenses		(169,209)	(112,122)	(310,213)	(222,027)
Impairment loss on financial assets		(23,281)	(5,843)	(25,234)	(5,843)
Other expenses		(35,790)	(14,013)	(49,488)	(17,615)
Other income		30,718	22,322	39,632	36,966
		(856,161)	(633,452)	(1,577,310)	(1,195,531)
Operating profit		440,700	188,073	624,515	258,248
Finance cost	12.2	(23,418)	(24,713)	(47,570)	(52,891)
Profit before income tax		417,282	163,360	576,945	205,357
Income tax expense	16	(118,236)	5,459	(184,939)	(10,231)
Profit after taxation		299,046	168,819	392,006	195,126
(Rupees)					
Earnings per share - basic and diluted		6.53	3.69	8.56	4.26

The annexed notes 1 to 20 form an integral part of these unconsolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Quarter Ended		Half Year Ended	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
..... (Rupees in '000)				
Profit after taxation	299,046	168,819	392,006	195,126
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	299,046	168,819	392,006	195,126

The annexed notes 1 to 20 form an integral part of these unconsolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Issued, subscribed and paid-up share capital	Reserves			Total
		Capital reserves	Revenue reserves	Total reserves	
		Share Premium	Accumulated profit		
----- (Rupees in '000) -----					
Balance as at July 01, 2023	458,111	1,225,860	1,186,722	2,412,582	2,870,693
Profit after taxation	-	-	195,126	195,126	195,126
Other comprehensive income for the period	-	-	-	-	-
Total comprehensive income for the period	-	-	195,126	195,126	195,126
Transactions with the owners					
Final cash dividend @ Rs. 0.54 per share for the year ended June 30, 2023	-	-	(24,738)	(24,738)	(24,738)
Balance as at December 31, 2023	<u>458,111</u>	<u>1,225,860</u>	<u>1,357,110</u>	<u>2,582,970</u>	<u>3,041,081</u>
Balance as at July 01, 2024	458,111	1,225,860	1,513,138	2,738,998	3,197,109
Profit after taxation	-	-	392,006	392,006	392,006
Other comprehensive income for the period	-	-	-	-	-
Total comprehensive income for the period	-	-	392,006	392,006	392,006
Transactions with the owners					
Final cash dividend @ Rs. 1.00 per share for the year ended June 30, 2024	-	-	(45,811)	(45,811)	(45,811)
Balance as at December 31, 2024	<u>458,111</u>	<u>1,225,860</u>	<u>1,859,333</u>	<u>3,085,193</u>	<u>3,543,304</u>

The annexed notes 1 to 20 form an integral part of these unconsolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)

FOR THE HALF YEAR ENDED DECEMBER 31, 2024

	Note	Half Year Ended	
		December 31, 2024	December 31, 2023
..... (Rupees in '000)			
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	327,246	304,422
Financial charges paid		(38,230)	(45,022)
Income tax paid		(96,800)	(146,887)
Gratuity paid		(3,433)	(25,918)
Receipts from long-term loans		(1,862)	(507)
Long-term deposits paid		(17,200)	(1,222)
Advance received against motor vehicles		755	390
		(156,770)	(219,166)
Net cash generated from operating activities		170,476	85,256
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant and equipment		(373,216)	(5,177)
Proceeds from disposal of property, plant and equipment		35,247	36,765
Short-term investment made		(16,838)	-
Net cash (used in) / generated from investing activities		(354,807)	31,588
CASH FLOWS FROM FINANCING ACTIVITIES			
Long-term financing obtained		177,601	6,782
Long-term financing repaid		(57,540)	(37,040)
Dividend paid		(45,811)	(24,694)
Principal portion of lease liabilities paid		(12,856)	(29,369)
Net cash generated from / (used in) financing activities		61,394	(84,321)
Net (decrease) / increase in cash and cash equivalent		(122,937)	32,523
Cash and cash equivalents at the beginning of the period		184,251	54,382
Cash and cash equivalents at the end of the period		61,314	86,905

The annexed notes 1 to 20 form an integral part of these unconsolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

**NOTES TO AND FORMING PART OF THE UNCONSOLIDATED CONDENSED INTERIM
FINANCIAL STATEMENTS (UNAUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2024**

1. THE COMPANY AND ITS OPERATIONS

1.1 Macter International Limited (the Company) was incorporated in Pakistan in 1992 as a private limited company under the repealed Companies Ordinance, 1984 (now Companies Act, 2017) and was converted into a public limited company in 2011. Effective from August 01, 2017 the Company has been listed on Pakistan Stock Exchange Limited.

1.1.1 The geographical locations and addresses of the Company's business units, including plants are as under:

- The Company's manufacturing plants are located at F-216, S.I.T.E., Karachi and E-40/A, S.I.T.E.; Karachi,
- The Company's commercial office is located at Bungalow No. 44-H, PECHS Block 6, Karachi and House No. NA-300, New Town, Nawaz Sharif Park, Rawalpindi; and
- The warehouse of the Company is situated at Plot No. F-217 & 217-A S.I.T.E., Karachi.

1.2 The principal activity of the Company is to manufacture and market pharmaceutical products. The registered office of the Company is situated at F-216 S.I.T.E., Karachi.

1.3 These unconsolidated condensed interim financial statements are the separate financial statements of the Company in which investment in subsidiary has been accounted for at cost less accumulated impairment losses, if any.

2. BASIS OF PREPARATION

2.1 Statement of compliance

These unconsolidated condensed interim financial statements of the Company have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by International Accounting Standard Board (IASB) as notified under the Act.
- Provisions of and directives issued under the Companies Act, 2017.
- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as are notified under the Act; and

Where the provisions of and directives issued under the Act or IFAS differ with the requirements of IAS 34, the provisions of and directives issued under the Act or IFAS have been followed.

These unconsolidated condensed interim financial statements do not include all the information and disclosures required in annual financial statements and should be read in conjunction with the Company's unconsolidated annual audited financial statements for the year ended June 30, 2024.

2.2 Functional and presentation currency

These unconsolidated condensed interim financial statements are presented in Pakistani Rupees which is the Company's functional and presentation currency and figures are rounded off to the nearest thousand of Rupees, unless otherwise disclosed.

2.3 Changes in accounting standards, interpretations and pronouncements

a) Standards and amendments to approved accounting and reporting standards that are effective

There are certain amendments and interpretations to the accounting and reporting standards which are mandatory for the Company's annual accounting period which began on July 1, 2024. However, these do not have any significant impact on the Company's financial reporting.

b) Standards and amendments to approved accounting and reporting standards that are not yet effective

There are certain amendments and interpretations to the accounting and reporting standards that will be mandatory for the Company's annual accounting periods beginning on or after July 1, 2025. However, these will not have any significant impact on the Company's financial reporting and, therefore, have not been disclosed in these unconsolidated condensed interim financial statements.

3. ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of these unconsolidated condensed interim financial statements is in conformity with the approved accounting standards which requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. However, actual results may differ from these estimates and assumptions.

During the preparation of these unconsolidated condensed interim financial statements, the significant judgements made by management in applying Company's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the unconsolidated annual audited financial statements for the year ended June 30, 2024.

4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The carrying value of all financial assets and liabilities reflected in these unconsolidated condensed interim financial statements approximate to their fair value.

5. MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies and the methods of computations adopted in the preparation of these unconsolidated condensed interim financial statements are consistent with those followed in the preparation of the Company's unconsolidated annual audited financial statements for the year ended June 30, 2024.

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000)	
		Un-audited	Audited
6. PROPERTY, PLANT AND EQUIPMENT			
Operating fixed assets	6.1	1,937,609	1,739,779
Capital work-in-progress	6.2	295,096	231,320
Right-of-use assets		81,071	96,135
		<u>2,313,776</u>	<u>2,067,234</u>

6.1 Details of additions and disposals to operating fixed assets are as follow:

	Additions (Cost)		Deletions (Net Book Value)	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
 (Rupees in '000)			
 (Un-audited)			
Buliding on leasehold land	406	1,951	-	-
Plant and machinery	6,070	17,858	-	-
Tools and equipment	2,917	542	-	-
Gas and other installation	126,947	2,988	-	-
Furniture and fixtures	2,121	1,303	-	-
Office equipment	272	2,234	-	-
Computer equipment	9,972	2,102	-	-
Motor vehicles	160,735	17,296	8,792	8,482
	<u>309,440</u>	<u>46,274</u>	<u>8,792</u>	<u>8,482</u>

6.2 Capital work-in-progress

	December 31, 2024			
	Building on leasehold land	Plant, machinery and other installations	Others	Total
 (Un-audited)			
 (Rupees in '000)			
Balance at beginning of the period	9,227	141,712	80,381	231,320
Capital expenditure incurred / advances made	(3,505)	162,450	181,708	340,653
Transferred to operating fixed assets	-	(116,683)	(160,194)	(276,877)
Balance at end of the period	5,722	187,479	101,895	295,096

	December 31, 2023			
	Building on leasehold land	Plant, machinery and other installations	Others	Total
 (Un-audited)			
 (Rupees in '000)			
Balance at beginning of the period	38,593	807	60,101	99,501
Capital expenditure incurred / advances made	5,130	3,762	1,174	10,066
Advances refunded	-	-	(26,298)	(26,298)
Transferred to operating fixed assets	(1,952)	(4,274)	(18,639)	(24,865)
Balance at end of the period	41,771	295	16,338	58,404

	Note	December 31, 2024 (Rupees in '000)	June 30, 2024 Audited
		Un-audited	

7. LONG-TERM INVESTMENT

Investment in subsidiary - at cost			
Misbah Cosmetic (Private) Limited			
Equity held: 79.84% (June 30, 2024: 79.84%)			
No. of shares: 30,000,000 (June 30, 2024: 30,000,000) of Rs.10 each	7.1	300,000	300,000

7.1 The subsidiary company is engaged in selling and distribution of cosmetic products.

Macter International Limited

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000) Un-audited	Audited
8. STOCK IN TRADE			
In hand			
- raw material		1,050,109	881,269
- packing material		402,104	264,295
- work-in-process		283,870	214,700
- finished goods		748,522	583,087
		<u>2,484,605</u>	<u>1,943,351</u>
In transit		349,582	137,527
		<u>2,834,187</u>	<u>2,080,878</u>
Less: Provision for slow moving and obsolete items	8.2	(92,964)	(108,916)
		<u>2,741,223</u>	<u>1,971,962</u>

8.1 As at December 31, 2024, stock of finished products has been written down by Rs. 5.86 million (June 30, 2024: Rs. 9.19 million) to arrive at its net realisable value of Rs. 17.90 million (June 30, 2024: Rs. 37.30 million).

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000) Un-audited	Audited
8.2 Provision for slow moving and obsolete items			
Balance at beginning of the period / year		108,916	124,383
Charge for the period / year		28,902	49,593
Write off during the period / year		(44,854)	(65,060)
Balance at end of the period / year		<u>92,964</u>	<u>108,916</u>
9. TRADE DEBTS - unsecured			
Considered good		576,439	389,899
Considered doubtful		133,623	112,680
		<u>710,062</u>	<u>502,579</u>
Less: Allowance for expected credit loss	9.1	(133,623)	(112,680)
		<u>576,439</u>	<u>389,899</u>

9.1 Allowance for expected credit loss

The movement in expected credit loss during the period / year is as follows:

Balance at the beginning of the period / year		112,680	138,005
Provision recognised during the period / year		20,943	5,843
Write offs during the period / year		-	(31,168)
		<u>20,943</u>	<u>(25,325)</u>
Balance at the end of the period / year		<u>133,623</u>	<u>112,680</u>
10. SHORT-TERM INVESTMENTS			
Term Deposit Mudaraba certificates	10.1	16,838	-

10.1 These carry profit at the rate of 17% per annum having maturity till August 2025.

Macter International Limited

		December 31, 2024	June 30, 2024
	Note (Rupees in '000)
		Un-audited	Audited
11. CASH AND BANK BALANCES			
Cash at Bank			
Conventional Bank			
- current account in local currency		1,033	1,902
Islamic Bank			
- current accounts		53,050	5,330
- saving accounts in local currency	11.1	6,648	176,469
- dividend accounts in local currency		583	550
		<u>60,281</u>	<u>182,349</u>
		<u>61,314</u>	<u>184,251</u>
11.1	These carry profit at the rates ranging from 5.87% to 10.01% (June 30, 2024: 11.01% to 19.00%) per annum.		
12. LONG-TERM FINANCING - secured			
Diminishing musharakah			
- on vehicles	12.1	541,195	421,134
Less: Current maturity shown under current liabilities		<u>(129,982)</u>	<u>(99,247)</u>
		<u>411,213</u>	<u>321,887</u>
12.1	These facilities have been obtained from First Habib Modaraba. These carry mark-up at the rates of 3 Months KIBOR + 1.00% (June 30, 2024: 3 Months KIBOR + 1.00% to 1.25%) per annum and are having maturity till December 2029 (June 30, 2024: June 2029). These facilities are secured by way of hypothecation charge over current / fixed assets of the Company.		
12.2	Finance cost on long-term financing for the period ended December 31, 2024 is Rs. 36.49 million (December 31, 2023: Rs. 35.56 million).		
13. TRADE AND OTHER PAYABLES			
Trade and other creditors		954,585	531,948
Advances from customers - contract liabilities		485,790	413,646
Refund liability		65,552	65,552
Accrued liabilities		265,646	236,052
Sindh Workers' Welfare Fund		11,902	12,721
Payable to provident fund		13,856	12,098
Withholding taxes payable		18,366	15,758
Sindh Workers' Profit Participation Fund		31,322	8,477
Central Research Fund		6,264	6,786
Auditors' remuneration		6,731	4,316
Accrued profit		1,815	2,471
Others		23,726	29,513
		<u>1,885,555</u>	<u>1,339,338</u>

14. CONTINGENCIES AND COMMITMENTS**14.1 Contingencies**

There is no change in the status of contingency as disclosed in note 23.1.1 to the unconsolidated annual audited financial statements for the year ended June 30, 2024 except the exposure under litigation has increased to Rs. 20.92 million (June 30, 2024: Rs. 18.03 million) during the period.

	December 31, 2024	June 30, 2024
 (Rupees in '000) (Rupees in '000)
	Un-audited	Audited
14.2 Commitments		
Capital Commitments	98,743	114,320
Outstanding letters of credit	729,605	453,080
Outstanding letters of guarantee	123,137	123,137

	December 31, 2024	December 31, 2023
 (Rupees in '000) (Rupees in '000)
 (Un-audited) (Un-audited)
15. REVENUE FROM CONTRACTS WITH CUSTOMERS		
Gross Sales		
Local	4,454,253	3,352,298
Export	389,977	192,538
	4,844,230	3,544,836
Toll manufacturing	185,636	120,643
	5,029,866	3,665,479
Less: Sales tax	(110,337)	(84,867)
	4,919,529	3,580,612

15. REVENUE FROM CONTRACTS WITH CUSTOMERS

	December 31, 2024	December 31, 2023
 (Rupees in '000) (Rupees in '000)
 (Un-audited) (Un-audited)
15.1		
This includes direct sales to government organizations amounting to Rs. 16.71 million (December 31, 2023: Rs. 4.32 million)		

	December 31, 2024	December 31, 2023
 (Rupees in '000) (Rupees in '000)
 (Un-audited) (Un-audited)
16. TAXATION		
Current - for the period	232,464	47,803
- prior year	(50,408)	(50,963)
Deferred	2,883	13,391
	184,939	10,231

	December 31, 2024	December 31, 2023
Note (Rupees in '000) (Un-audited)
17. CASH GENERATED FROM OPERATIONS		
Profit before income tax	576,945	205,357
Adjustments of non cash and other items:		
Depreciation on operating fixed assets	102,818	100,038
Depreciation on right-of-use assets	16,888	23,096
Amortization	293	557
Financial charges	37,574	40,478
Mark-up on lease liabilities	9,830	504
Finance Cost on Provision for GIDC	166	11,909
Provision for gratuity	23,853	30,773
Gain on disposal of property, plant and equipment	(26,455)	(28,283)
Provision for slow moving and obsolete stock-in-trade 8.2	28,902	(44,207)
Allowance for expected credit loss on financial instruments	25,234	(25,325)
Change in working capital 17.1	(468,802)	(10,475)
	<u>327,246</u>	<u>304,422</u>
17.1 Change in working capital		
(Increase) / decrease in current assets		
Stores and spares	(4,728)	(1,246)
Stock-in-trade	(798,163)	(313,480)
Trade debts	(211,774)	8,232
Loans and advances	22,050	(49,889)
Trade deposits, prepayments and other receivables	(25,427)	(22,622)
Sales tax refundable	-	19,057
	<u>(1,018,042)</u>	<u>(359,948)</u>
Increase in current liabilities		
Trade and other payables	526,400	349,473
Sales tax payable	22,840	-
	<u>549,240</u>	<u>349,473</u>
	<u>(468,802)</u>	<u>(10,475)</u>
18. FINANCIAL RISK MANAGEMENT AND FAIR VALUE DISCLOSURES		
<p>These unconsolidated condensed interim financial statements do not include all financial risk management information and disclosures which are required in the unconsolidated annual financial statements and should be read in conjunction with the Company's unconsolidated annual audited financial statements for the year ended June 30, 2024. There has been no change in any risk management policies since the year end.</p>		

19. TRANSACTIONS WITH RELATED PARTIES

Related parties of the Company comprise of the subsidiary company, employee benefit fund, directors and key management personnel. Details of transactions with related parties during the period are as follows:

		Half Year Ended	
		December 31, 2024	December 31, 2023
	 (Rupees in '000)	
	 (Un-audited)	
Relationship	Nature of transactions		
Provident Fund	Contribution made	<u>35,654</u>	<u>30,205</u>
Non-Executive Director	Fee for attending meetings	<u>325</u>	<u>1,550</u>
	Dividend	<u>285</u>	<u>154</u>
Key Management Personnel	Salary and other benefits	<u>165,299</u>	<u>180,972</u>
	Dividend	<u>30,226</u>	<u>16,344</u>
Misbah Cosmetics Private Limited	Purchases	<u>962</u>	<u>1,082</u>
	Payments	<u>-</u>	<u>1,005</u>
	Payable	<u>962</u>	<u>77</u>

20. DATE OF AUTHORIZATION FOR ISSUE

These unconsolidated condensed interim financial statements were authorized for issue on February 22, 2025 by the Board of Directors of the Company.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

This page left blank intentionally.

**CONSOLIDATED CONDENSED INTERIM
FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED
DECEMBER 31, 2024**

CONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION (UN-AUDITED)

AS AT DECEMBER 31, 2024

	Note	December 31,	June 30,
		2024	2024
	 (Rupees in '000)	
		Un-audited	Audited
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	6	2,337,832	2,090,217
Intangible assets		44,239	46,048
Long-term loans		3,691	1,829
Long-term deposits		93,315	75,240
Deferred taxation - net		11,168	14,052
		<u>2,490,245</u>	<u>2,227,386</u>
CURRENT ASSETS			
Stores and spares		22,842	18,114
Stock-in-trade	7	2,826,921	2,022,439
Trade debts	8	704,225	472,307
Loans and advances		214,083	278,126
Trade deposits, prepayments and other receivables		117,193	91,205
Sales tax refundable		-	9,626
Taxation - net		-	60,433
Short-term investments	9	16,838	-
Cash and bank balances	10	80,390	187,673
		<u>3,982,492</u>	<u>3,139,923</u>
TOTAL ASSETS		<u>6,472,737</u>	<u>5,367,309</u>
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Issued, subscribed and paid-up capital		458,111	458,111
Capital reserve		1,225,860	1,225,860
Revenue reserve - accumulated profit		1,620,372	1,270,529
Equity attributable to the owner's of the Holding Company		3,304,343	2,954,500
Non controlling interest		4,846	3,583
		<u>3,309,189</u>	<u>2,958,083</u>
NON-CURRENT LIABILITIES			
Deferred liabilities		285,980	262,834
Long-term financing	11	448,318	361,087
Lease liabilities		57,893	85,862
		<u>792,191</u>	<u>709,783</u>
CURRENT LIABILITIES			
Trade and other payables	12	1,952,532	1,377,418
Short-term borrowings		129,146	105,000
Current portion of long-term financing	11	134,172	103,437
Current portion of lease liabilities		33,815	27,554
Current portion of long term provision		85,650	85,484
Sales tax payable		9,899	-
Taxation - net		25,560	-
Unclaimed dividends		583	550
		<u>2,371,357</u>	<u>1,699,443</u>
TOTAL LIABILITIES		<u>3,163,548</u>	<u>2,409,226</u>
CONTINGENCIES AND COMMITMENTS	13		
TOTAL EQUITY AND LIABILITIES		<u>6,472,737</u>	<u>5,367,309</u>

The annexed notes 1 to 20 form an integral part of these consolidated condensed interim financial statements.


CHIEF FINANCIAL OFFICER


CHIEF EXECUTIVE


DIRECTOR

CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE PERIOD ENDED DECEMBER 31, 2024

	Note	Quarter Ended		Half Year Ended	
		December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
..... (Rupees in '000)					
Revenue from contracts with customers	15	2,885,024	2,058,341	5,143,503	3,807,782
Cost of sales		(1,508,666)	(1,159,373)	(2,802,838)	(2,223,094)
Gross profit		1,376,358	898,968	2,340,665	1,584,688
Selling and Distribution expenses		(719,503)	(587,273)	(1,343,521)	(1,096,999)
Administrative expenses		(169,232)	(113,714)	(312,443)	(226,037)
Impairment loss on financial assets		(23,281)	(5,843)	(25,234)	(5,843)
Other expenses		(35,790)	(14,013)	(49,488)	(17,615)
Other income		31,072	22,322	39,986	39,451
		(916,734)	(698,521)	(1,690,700)	(1,307,043)
Operating profit		459,624	200,447	649,965	277,645
Finance cost	11.3	(31,498)	(30,752)	(65,297)	(64,124)
Profit before income tax		428,126	169,695	584,668	213,521
Income tax expense	16	(119,647)	3,768	(187,751)	(13,073)
Profit after taxation		308,479	173,463	396,917	200,448
..... (Rupees)					
Earnings per share - basic and diluted		6.69	3.78	8.64	4.35
..... (Rupees in '000)					
Attributable to:					
Owners of the Holding Company		306,441	173,190	395,654	199,102
Non-controlling interest		2,038	273	1,263	1,346
		308,479	173,463	396,917	200,448

The annexed notes 1 to 20 form an integral part of these consolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

**CONSOLIDATED CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE PERIOD ENDED DECEMBER 31, 2024**

	Quarter Ended		Half Year Ended	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
..... (Rupees in '000)				
Profit after taxation	308,479	173,463	396,917	200,448
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	<u>308,479</u>	<u>173,463</u>	<u>396,917</u>	<u>200,448</u>
Attributable to:				
Owners of the Holding Company	306,441	173,190	395,654	199,102
Non-controlling interest	2,038	273	1,263	1,346
	<u>308,479</u>	<u>173,463</u>	<u>396,917</u>	<u>200,448</u>

The annexed notes 1 to 20 form an integral part of these consolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE PERIOD ENDED DECEMBER 31, 2024

	Issued, subscribed and paid-up share capital	Reserves			Non Controlling Interest	Total
		Capital reserves	Revenue reserves	Total reserves		
		Share Premium	Accumulated profit			
----- (Rupees in '000) -----						
Balance as at July 01, 2023	458,111	1,225,860	965,136	2,190,996	8,209	2,657,316
Profit after taxation	-	-	199,102	199,102	1,346	200,448
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	199,102	199,102	1,346	200,448
Transactions with the owners						
Final cash dividend @ Rs. 0.54 per share for the year ended June 30, 2023	-	-	(24,738)	(24,738)	-	(24,738)
Balance as at December 31, 2023	<u>458,111</u>	<u>1,225,860</u>	<u>1,139,500</u>	<u>2,365,360</u>	<u>9,555</u>	<u>2,833,026</u>
Balance as at July 01, 2024	458,111	1,225,860	1,270,529	2,496,389	3,583	2,958,083
Profit after taxation	-	-	395,654	395,654	1,263	396,917
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	395,654	395,654	1,263	396,917
Transactions with the owners						
Final cash dividend @ Rs. 1.00 per share for the year ended June 30, 2024	-	-	(45,811)	(45,811)	-	(45,811)
Balance as at December 31, 2024	<u>458,111</u>	<u>1,225,860</u>	<u>1,620,372</u>	<u>2,846,232</u>	<u>4,846</u>	<u>3,309,189</u>

The annexed notes 1 to 20 form an integral part of these consolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)

FOR THE PERIOD ENDED DECEMBER 31, 2024

	Note	Half Year Ended	
		December 31, 2024	December 31, 2023
..... (Rupees in '000)			
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	342,378	264,371
Financial charges paid		(54,574)	(53,518)
Income tax paid		(98,875)	(144,534)
Gratuity paid		(3,433)	(25,918)
Receipts from long-term loans		(1,862)	(507)
Long-term deposits paid		(18,075)	(916)
Advance received against motor vehicles		755	390
		<u>(176,064)</u>	<u>(225,003)</u>
Net cash generated from operating activities		166,314	39,368
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant & equipment		(375,873)	(8,838)
Proceeds from disposal of operating fixed asset		35,668	39,605
Short-term investment made		(16,838)	-
Net cash (used in) / generated from investing activities		(357,043)	30,767
CASH FLOWS FROM FINANCING ACTIVITIES			
Short-term borrowings obtained		24,946	50,773
Short-term borrowings repaid		(800)	-
Long-term financing obtained		177,601	6,782
Long-term financing repaid		(59,635)	(38,883)
Dividend paid		(45,811)	(24,738)
Principal portion of lease liabilities paid		(12,855)	(29,369)
Net cash generated from / (used in) financing activities		83,446	(35,435)
Net (decrease) / increase in cash and cash equivalent		(107,283)	34,700
Cash and cash equivalents at the beginning of the period		187,673	54,974
Cash and cash equivalents at the end of the period		80,390	89,674

The annexed notes 1 to 20 form an integral part of these consolidated condensed interim financial statements.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR

**NOTES TO AND FORMING PART OF THE
CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
FOR THE PERIOD ENDED DECEMBER 31, 2024**

1. THE COMPANY AND ITS OPERATIONS

The Group consist of Macter International Limited ("the Holding Company") and Misbah Cosmetics (Private) Limited ("the Subsidiary Company"). Brief profile of the Holding Company and the Subsidiary Company is given below:

1.1 Macter International Limited

1.1.1 Macter International Limited (the Company) was incorporated in Pakistan in 1992 as a private limited company under the repealed Companies Ordinance, 1984 (now Companies Act, 2017) and was converted into a public limited company in 2011. Effective from August 01, 2017 the Company has been listed on Pakistan Stock Exchange Limited.

1.1.2 The geographical locations and addresses of the Company's business units, including plants are as under:

- The Company's manufacturing plants are located at F-216, S.I.T.E., Karachi and E-40/A, S.I.T.E.; Karachi,
- The Company's commercial office is located at Bungalow No # 44-H, PECHS Block 6, Karachi and House No # NA-300, New Town, Nawaz Sharif Park, Rawalpindi; and
- The warehouse of the Company is situated at Plot No # F-217 & 217-A S.I.T.E., Karachi.

1.1.3 The principal activity of the Company is to manufacture and market pharmaceutical products. The registered office of the Company is situated at F-216 S.I.T.E., Karachi.

1.2 Misbah Cosmetics (Private) Limited

1.2.1 The Subsidiary Company is a Private Limited Company incorporated in Pakistan on June 09, 2014 under the repealed Companies Ordinance, 1984 (now Companies Act, 2017). The geographical location and registered office of the Company is situated at F-216, S.I.T.E., Karachi.

	Effective %age of holding	
	December 31, 2024 Un-audited	June 30, 2024 Audited
Misbah Cosmetics (Private) Limited	79.84%	79.84%

1.2.2 The principal activity of the Subsidiary Company is selling and distribution of cosmetic products in Pakistan.

2. BASIS OF PREPARATION

2.1 Statement of compliance

These consolidated condensed interim financial statements of the Group have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by International Accounting Standard Board (IASB) as notified under the Act.
- Provisions of and directives issued under the Companies Act, 2017.
- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as are notified under the Act; and

Where the provisions of and directives issued under the Act or IFAS differ with the requirements of IAS 34, the provisions of and directives issued under the Act or IFAS have been followed.

These consolidated condensed interim financial statements do not include all the information and disclosures required in annual financial statements and should be read in conjunction with the Group's consolidated annual audited financial statements for the year ended June 30, 2024.

2.2 Functional and presentation currency

These consolidated condensed interim financial statements are presented in Pakistani Rupees which is the Group's functional and presentation currency and figures are rounded off to the nearest thousand of Rupees, unless otherwise disclosed.

2.3 Changes in accounting standards, interpretations and pronouncements

(a) Standards and amendments to approved accounting and reporting standards that are effective

There are certain amendments and interpretations to the accounting and reporting standards which are mandatory for the Group's annual accounting period which began on July 1, 2024. However, these do not have any significant impact on the Group's financial reporting.

(b) Standards and amendments to approved accounting and reporting standards that are not yet effective

There are certain amendments and interpretations to the accounting and reporting standards that will be mandatory for the Group's annual accounting periods beginning on or after July 1, 2025. However, these will not have any impact on the Group's financial reporting and, therefore, have not been disclosed in these consolidated condensed interim financial statements.

3. ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of these consolidated condensed interim financial statements is in conformity with the approved accounting standards which requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. However, actual results may differ from these estimates and assumptions.

During the preparation of these consolidated condensed interim financial statements, the significant judgements made by management in applying Group's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the consolidated annual audited financial statements for the year ended June 30, 2024.

4. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The carrying value of all financial assets and liabilities reflected in these consolidated condensed interim financial statements approximate to their fair value.

5. MATERIAL ACCOUNTING POLICIES

The accounting policies and the methods of computations adopted in the preparation of these consolidated condensed interim financial statements are consistent with those followed in the preparation of the Group's consolidated annual audited financial statements for the year ended June 30, 2024.

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000)	
6. PROPERTY, PLANT AND EQUIPMENT		Un-audited	Audited
Operating fixed assets	6.1	1,961,665	1,762,762
Capital work-in-progress	6.2	295,096	231,320
Right-of-use assets		81,071	96,135
		<u>2,337,832</u>	<u>2,090,217</u>

6.1 Details of additions and disposals to operating fixed assets are as follow:

	Additions (Cost)		Deletions (Net Book Value)	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
 (Rupees in '000)			
 (Un-audited)			
Building on leasehold land	406	1,951		
Plant and machinery	6,200	17,993	-	-
Tools and equipment	2,917	542	-	-
Gas and other installation	126,947	2,988	-	-
Furniture and fixtures	4,215	3,544	-	-
Office equipment	435	2,249	-	-
Computer equipment	10,242	2,407	-	18
Motor vehicles	160,735	18,263	8,859	8,482
	<u>312,097</u>	<u>49,937</u>	<u>8,859</u>	<u>8,500</u>

6.2 Capital work-in-progress

	December 31, 2024			
	Building on leasehold land	Plant, machinery and others	Others	Total
 (Rupees in '000)			
Balance at beginning of the period	9,227	141,712	80,381	231,320
Capital expenditure incurred / advances made	(3,505)	162,450	181,708	340,653
Transferred to operating fixed assets	-	(116,683)	(160,194)	(276,877)
Balance at end of the period	<u>5,722</u>	<u>187,479</u>	<u>101,895</u>	<u>295,096</u>

	December 31, 2023			
	Building on leasehold land	Plant, machinery and others	Others	Total
 (Rupees in '000)			
 (Un-audited)			
Balance at beginning of the period	38,593	807	60,101	99,501
Capital expenditure incurred / advances made	5,130	3,762	1,174	10,066
Advances refunded	-	-	(26,298)	(26,298)
Transferred to operating fixed assets	(1,952)	(4,274)	(18,639)	(24,865)
Balance at end of the period	<u>41,771</u>	<u>295</u>	<u>16,338</u>	<u>58,404</u>

Macter International Limited

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000)	
		Un-audited	Audited
7. STOCK IN TRADE			
In hand			
- raw material		1,050,109	881,269
- packing material		402,104	264,295
- work-in-process		283,870	214,700
- finished goods		808,056	633,564
		<u>2,544,139</u>	<u>1,993,828</u>
In transit		375,746	137,527
		<u>2,919,885</u>	<u>2,131,355</u>
Less: Provision for slow moving and obsolete items	7.2	(92,964)	(108,916)
		<u>2,826,921</u>	<u>2,022,439</u>

7.1 As at December 31, 2024, stock of finished products has been written down by Rs. 5.86 million (June 30, 2024: Rs. 9.19 million) to arrive at its net realisable value of Rs. 17.90 million (June 30, 2024: Rs. 37.30 million).

	Note	December 31, 2024	June 30, 2024
	 (Rupees in '000)	
		Un-audited	Audited
7.2 Provision for slow moving and obsolete items			
Balance at beginning of the period / year		108,916	134,462
Charge for the period / year		28,902	50,076
Write off during the period / year		(44,854)	(75,622)
Balance at end of the period / year		<u>92,964</u>	<u>108,916</u>
8. TRADE DEBTS - unsecured			
Considered good		704,225	472,308
Considered doubtful		147,209	127,808
		851,434	600,116
Less: Allowance for expected credit loss	8.1	(147,209)	(127,809)
		<u>704,225</u>	<u>472,307</u>

8.1 Allowance for expected credit loss

The movement in expected credit loss during the period / year is as follows:

Balance at the beginning of the period / year	127,809	147,296
Provision recognized during the period / year	19,400	11,681
Write offs during the period / year	-	(31,168)
	<u>19,400</u>	<u>(19,487)</u>
Balance at the end of the period / year	<u>147,209</u>	<u>127,809</u>

Macter International Limited

		December 31, 2024	June 30, 2024
	 (Rupees in '000) (Rupees in '000)
		Un-audited	Audited
9. SHORT-TERM INVESTMENTS			
Term Deposit Mudaraba certificates	9.1	<u>16,838</u>	<u>-</u>

9.1 These carry profit at the rate of 17.00% per annum having maturity till August 2025.

		December 31, 2024	June 30, 2024
	 (Rupees in '000) (Rupees in '000)
		Un-audited	Audited
10. CASH AND BANK BALANCES			
Cash at Bank			
Conventional Bank			
- current account in local currency		1,033	5,324
Islamic Bank			
- current accounts		72,126	5,330
- saving accounts in local currency	10.1	6,648	176,469
- dividend accounts in local currency		583	550
		<u>79,357</u>	<u>182,349</u>
		<u>80,390</u>	<u>187,673</u>

10.1 These carry profit at the rates ranging from 5.87% to 10.01% (June 30, 2024 : 11.01% to 19.00%) per annum.

		December 31, 2024	June 30, 2024
	 (Rupees in '000) (Rupees in '000)
		Un-audited	Audited
11. LONG-TERM FINANCING			
Loan from a related party	11.1	<u>38,992</u>	40,833
Secured			
Diminishing musharakah on			
- vehicles	11.2	543,498	423,691
		<u>582,490</u>	464,524
Less: Current maturity shown under current liabilities		<u>(134,172)</u>	(103,437)
		<u>448,318</u>	<u>361,087</u>

11.1 This represents loan obtained from a director of the Parent Company to meet working capital requirement, under mark-up arrangements. It carries profit at 90 days average of 12 Months KIBOR for 3rd calendar Quarter-2023 which was fixed for one year starting from August as 22.32% per annum (June 30, 2024: 90 days average of 12 Months KIBOR for 3rd calendar Quarter-2023 which was fixed for one year starting from August as 22.32% per annum). The profit and principle are payable on monthly basis.

11.2 These facilities have been obtained from First Habib Modaraba. These carry mark-up at the rates of 3 Months KIBOR + 1.00% (June 30, 2024: 3 Months KIBOR + 1.00% to 1.25%) per annum and are having maturity till December 2029 (June 30, 2024: June 2029). These facilities are secured by way of hypothecation charge over current / fixed assets of the Company.

11.3 Finance cost on long-term financing for the period ended December 31, 2024 is Rs.41.63 million (December 31, 2023: Rs.40.87 million).

Note	December 31, 2024	June 30, 2024
 (Rupees in '000) (Rupees in '000)
	Un-audited	Audited
12. TRADE AND OTHER PAYABLES		
Trade and other creditors	988,418	546,863
Advances from customers - contract liabilities	486,565	414,160
Refund liability	65,552	65,552
Accrued liabilities	291,476	250,058
Sindh Workers' Welfare Fund	11,902	12,721
Payable to provident fund	13,856	12,098
Withholding taxes payable	18,366	19,247
Sindh Workers' Profit Participation Fund	31,322	8,477
Central Research Fund	6,264	6,786
Auditors' remuneration	6,731	4,316
Accrued profit	8,354	7,627
Others	23,726	29,513
	<u>1,952,532</u>	<u>1,377,418</u>

13. CONTINGENCIES AND COMMITMENTS

13.1 Contingencies

There is no change in the status of contingency as disclosed in note 23.1.1 to the consolidated annual audited financial statements for the year ended June 30, 2024 except the exposure under litigation has increased to Rs 20.92 million (June 30, 2024: Rs. 18.03 million) during the period.

	December 31, 2024	June 30, 2024
 (Rupees in '000) (Rupees in '000)
	Un-audited	Audited
13.2 Commitments		
Capital Commitments	98,743	114,320
Outstanding letters of credit	729,605	453,080
Outstanding letters of guarantee	123,137	123,137

ljarah rental commitment outstanding as at December 31, 2024 amounting to Rs. 2.887 million.

14. OPERATING SEGMENTS

	Pharmaceuticals		Cosmetics and Fragrance		Total	
	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023	December 31, 2024	December 31, 2023
..... (Rupees in '000)						
Turnover	4,919,529	3,580,613	224,936	227,169	5,144,465	3,807,782
Inter segment revenue	-	-	-	-	(962)	-
Net turnover	4,919,529	3,580,613	224,936	227,169	5,143,503	3,807,782
Cost of sales	(2,717,704)	(2,126,834)	(86,096)	(96,260)	(2,803,800)	(2,223,094)
Inter segment expense	-	-	-	-	962	-
Net cost of sales	(2,717,704)	(2,126,834)	(86,096)	(96,260)	(2,802,838)	(2,223,094)
Gross profit	2,201,825	1,453,779	138,840	130,909	2,340,665	1,584,688
Other income	39,632	36,966	354	2,485	39,986	39,451
Selling and Distribution expenses	(1,232,007)	(987,012)	(110,160)	(109,987)	(1,342,167)	(1,095,645)
Administrative expenses	(310,213)	(222,027)	(2,230)	(2,656)	(312,443)	(226,037)
Impairment loss on financial assets	(25,234)	(5,843)	-	-	(25,234)	(5,843)
Other expenses	(49,488)	(17,615)	-	-	(49,488)	(17,615)
Finance cost	(47,570)	(52,891)	(17,727)	(11,233)	(65,297)	(64,124)
Unallocated expense (brand amortization)	-	-	-	-	(1,354)	(1,354)
Profit before tax	576,945	205,357	9,077	9,518	584,668	213,521

	Pharmaceuticals		Cosmetics and Fragrance		Total	
	December 31, 2024 Un-audited	June 30, 2024 Audited	December 31, 2024 Un-audited	June 30, 2024 Audited	December 31, 2024 Un-audited	June 30, 2024 Audited
..... (Rupees in '000)						
Segments assets	6,163,913	5,113,083	266,979	211,027	6,430,892	5,324,110
Unallocated assets	-	-	-	-	41,845	43,199
Segment liabilities	2,919,647	2,215,974	243,901	193,252	3,163,548	2,409,226

	Note	Half Year Ended	
		December 31, 2024	December 31, 2023
	 (Rupees in '000) (Un-audited)
15. REVENUE FROM CONTRACTS WITH CUSTOMERS			
Gross Sales			
Local	15.1	4,731,958	3,352,298
Export		389,977	475,359
		5,121,935	3,827,657
Toll manufacturing		185,636	120,643
		5,307,571	3,948,300
Less: Sales tax		(164,068)	(140,518)
		5,143,503	3,807,782

15.1 This include sales to government organizations amounting to Rs. 16.71 million (December 31, 2023: Rs. 4.32 million)

	Note	Half Year Ended	
		December 31, 2024	December 31, 2023
	 (Rupees in '000) (Un-audited)
16. TAXATION			
Current - for the period		235,276	50,645
- prior year		(50,408)	(50,963)
Deferred		2,883	13,391
		187,751	13,073

17. CASH GENERATED FROM OPERATIONS			
Profit before income tax		584,668	213,521
Adjustments of non cash and other items:-			
Depreciation on operating fixed assets		104,335	101,121
Depreciation on right-of-use assets		16,888	23,096
Amortization		1,810	2,072
Financial charges		55,301	51,711
Mark-up on lease liabilities		9,830	504
Finance Cost on Provision for GIDC		166	11,909
Provision for gratuity		25,824	32,391
Gain on disposal of property, plant and equipment		(26,809)	(30,768)
Provision for slow moving and obsolete stock-in-trade	7.2	28,902	(44,207)
Allowance for expected credit loss on financial instruments		23,691	(25,325)
Change in working capital	17.1	(482,228)	(71,654)
		342,378	264,371

Macter International Limited

	December 31, 2024	December 31, 2023
Note (Rupees in '000) (Un-audited)
17.1 Change in working capital		
(Increase) / decrease in current assets		
Stores and spares	(4,728)	(1,246)
Stock-in-trade	(833,384)	(374,622)
Trade debts	(255,609)	(64,261)
Loans and advances	64,043	(57,329)
Trade deposits, prepayments and other receivables	(25,988)	(24,935)
Sales tax refundable	-	19,057
	(1,055,666)	(503,336)
Increase in current liabilities		
Trade and other payables	553,913	431,682
Sales tax payable	19,525	-
	573,438	431,682
	(482,228)	(71,654)

18. FINANCIAL RISK MANAGEMENT AND FAIR VALUE DISCLOSURES

These consolidated condensed interim financial statements do not include all financial risk management information and disclosures which are required in the consolidated annual financial statements and should be read in conjunction with the Group's consolidated annual audited financial statements for the year ended June 30, 2024. There have been no change in any risk management policies since the year end.

19. TRANSACTIONS WITH RELATED PARTIES

Related parties of the Group comprise of the subsidiary company, employee benefit fund, directors and key management personnel. Details of transactions with related parties during the period are as follows:

		Half Year Ended	
		December 31, 2024	December 31, 2023
	 (Rupees in '000) (Un-audited)
Relationship	Nature of transactions		
Provident Fund	Contribution made	35,654	30,205
Non-Executive Director	Fee for attending meetings	325	1,550
	Dividend	285	154
Key Management Personnel	Salary and other benefits	173,135	188,038
	Dividend	30,226	16,344
	Repayment of loan	921	921
Depilex (Private) Limited (Common directorship)	Sales made by the Subsidiary Company	4,938	3,089
Balances Outstanding			
Depilex (Private) Limited (Common directorship)	Amount due to the Subsidiary Company	5,609	2,344

20. Date of authorization for issue

These consolidated condensed interim financial statements were authorized for issue on February 22, 2025 by the Board of Directors of the Group.



CHIEF FINANCIAL OFFICER



CHIEF EXECUTIVE



DIRECTOR



Printed by: SAAM PRINTERS

Macter International Limited
F-216 SITE, Karachi - Pakistan
www.macter.com